Literature DB >> 34661137

The Chromosome 13 Conundrum in Multiple Myeloma.

Brian A Walker1.   

Abstract

In this issue of Blood Cancer Discovery, Chesi and colleagues have performed a series of mouse experiments, combined with patient sample analysis, to delineate the role of del(13) in multiple myeloma. They identify loss of the miRNA cluster MIR15A/16-1 as critical for myelomagenesis and progression of disease. See related article by Chesi et al., p. 68. ©2020 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 34661137      PMCID： PMC8500709          DOI： 10.1158/2643-3249.BCD-20-0081

Source DB:  PubMed          Journal:  Blood Cancer Discov        ISSN： 2643-3230


  9 in total

1.  BRAF and DIS3 Mutations Associate with Adverse Outcome in a Long-term Follow-up of Patients with Multiple Myeloma.

Authors:  Eileen M Boyle; Cody Ashby; Ruslana G Tytarenko; Shayu Deshpande; Hongwei Wang; Yan Wang; Adam Rosenthal; Jeffrey Sawyer; Erming Tian; Erin Flynt; Antje Hoering; Sarah K Johnson; Michael W Rutherford; Christopher P Wardell; Michael A Bauer; Charles Dumontet; Thierry Facon; Sharmilan Thanendrarajan; Carolina D Schinke; Maurizio Zangari; Frits van Rhee; Bart Barlogie; David Cairns; Graham Jackson; Anjan Thakurta; Faith E Davies; Gareth J Morgan; Brian A Walker
Journal:  Clin Cancer Res       Date:  2020-01-27       Impact factor: 12.531

2.  Ibrutinib and Venetoclax for First-Line Treatment of CLL.

Authors:  Nitin Jain; Michael Keating; Philip Thompson; Alessandra Ferrajoli; Jan Burger; Gautam Borthakur; Koichi Takahashi; Zeev Estrov; Nathan Fowler; Tapan Kadia; Marina Konopleva; Yesid Alvarado; Musa Yilmaz; Courtney DiNardo; Prithviraj Bose; Maro Ohanian; Naveen Pemmaraju; Elias Jabbour; Koji Sasaki; Rashmi Kanagal-Shamanna; Keyur Patel; Jeffrey Jorgensen; Naveen Garg; Xuemei Wang; Katrina Sondermann; Nichole Cruz; Chongjuan Wei; Ana Ayala; William Plunkett; Hagop Kantarjian; Varsha Gandhi; William Wierda
Journal:  N Engl J Med       Date:  2019-05-30       Impact factor: 91.245

3.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia.

Authors:  George Adrian Calin; Calin Dan Dumitru; Masayoshi Shimizu; Roberta Bichi; Simona Zupo; Evan Noch; Hansjuerg Aldler; Sashi Rattan; Michael Keating; Kanti Rai; Laura Rassenti; Thomas Kipps; Massimo Negrini; Florencia Bullrich; Carlo M Croce
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-14       Impact factor: 11.205

4.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value.

Authors:  Brian A Walker; Paola E Leone; Laura Chiecchio; Nicholas J Dickens; Matthew W Jenner; Kevin D Boyd; David C Johnson; David Gonzalez; Gian Paolo Dagrada; Rebecca K M Protheroe; Zoe J Konn; David M Stockley; Walter M Gregory; Faith E Davies; Fiona M Ross; Gareth J Morgan
Journal:  Blood       Date:  2010-07-08       Impact factor: 22.113

5.  The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.

Authors:  Ulf Klein; Marie Lia; Marta Crespo; Rachael Siegel; Qiong Shen; Tongwei Mo; Alberto Ambesi-Impiombato; Andrea Califano; Anna Migliazza; Govind Bhagat; Riccardo Dalla-Favera
Journal:  Cancer Cell       Date:  2010-01-07       Impact factor: 31.743

6.  AID-dependent activation of a MYC transgene induces multiple myeloma in a conditional mouse model of post-germinal center malignancies.

Authors:  Marta Chesi; Davide F Robbiani; Michael Sebag; Wee Joo Chng; Maurizio Affer; Rodger Tiedemann; Riccardo Valdez; Stephen E Palmer; Stephanie S Haas; A Keith Stewart; Rafael Fonseca; Richard Kremer; Giorgio Cattoretti; P Leif Bergsagel
Journal:  Cancer Cell       Date:  2008-02       Impact factor: 31.743

7.  Initial genome sequencing and analysis of multiple myeloma.

Authors:  Michael A Chapman; Michael S Lawrence; Jonathan J Keats; Kristian Cibulskis; Carrie Sougnez; Anna C Schinzel; Christina L Harview; Jean-Philippe Brunet; Gregory J Ahmann; Mazhar Adli; Kenneth C Anderson; Kristin G Ardlie; Daniel Auclair; Angela Baker; P Leif Bergsagel; Bradley E Bernstein; Yotam Drier; Rafael Fonseca; Stacey B Gabriel; Craig C Hofmeister; Sundar Jagannath; Andrzej J Jakubowiak; Amrita Krishnan; Joan Levy; Ted Liefeld; Sagar Lonial; Scott Mahan; Bunmi Mfuko; Stefano Monti; Louise M Perkins; Robb Onofrio; Trevor J Pugh; S Vincent Rajkumar; Alex H Ramos; David S Siegel; Andrey Sivachenko; A Keith Stewart; Suzanne Trudel; Ravi Vij; Douglas Voet; Wendy Winckler; Todd Zimmerman; John Carpten; Jeff Trent; William C Hahn; Levi A Garraway; Matthew Meyerson; Eric S Lander; Gad Getz; Todd R Golub
Journal:  Nature       Date:  2011-03-24       Impact factor: 49.962

8.  Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Authors:  S S Chavan; J He; R Tytarenko; S Deshpande; P Patel; M Bailey; C K Stein; O Stephens; N Weinhold; N Petty; D Steward; L Rasche; M Bauer; C Ashby; E Peterson; S Ali; J Ross; V A Miller; P Stephens; S Thanendrarajan; C Schinke; M Zangari; F van Rhee; B Barlogie; T I Mughal; F E Davies; G J Morgan; B A Walker
Journal:  Blood Cancer J       Date:  2017-02-24       Impact factor: 11.037

9.  Monosomic loss of MIR15A/MIR16-1 is a driver of multiple myeloma proliferation and disease progression.

Authors:  Marta Chesi; Caleb K Stein; Victoria M Garbitt; Meaghen E Sharik; Yan W Asmann; Matteo Bergsagel; Daniel L Riggs; Seth J Welsh; Erin W Meermeier; Shaji K Kumar; Esteban Braggio; P Leif Bergsagel
Journal:  Blood Cancer Discov       Date:  2020-07
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.